Evidence map›Paper›PMID 39308683›Full record

ArticleJournal of Cancer2024

miR-141-3p promotes paclitaxel resistance by attenuating ferroptosis via the Keap1-Nrf2 signaling pathway in breast cancer.

Wan-Li Duan, Xue-Jie Wang, Ai Guo, Li-Hui Gu, Zhi-Mei Sheng, Hao Luo, Li-Xia Yang, Wen-Hao Wang, Bao-Gang Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Ferroptosis-related signaling pathways in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2025
    Review
  9. NFE2L2 and ferroptosis resistance in cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wan-Li DuanMedical Research Center, Shaoxing People's Hospital, No.568, Zhongxing North Road, Shaoxing 312000, Zhejiang Province, China.
Xue-Jie WangDepartment of Pathology, Shaoxing People's Hospital, No.568, Zhongxing North Road, Shaoxing 312000, Zhejiang Province, China.
Ai GuoDepartment of Diagnostic Pathology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang 261041, China.
Li-Hui GuDepartment of Diagnostic Pathology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang 261041, China.
Zhi-Mei ShengDepartment of Pathology, Affiliated Hospital of Shandong Second Medical University, Weifang 261041, Shandong, China.
Hao LuoDepartment of Diagnostic Pathology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang 261041, China.
Li-Xia YangMedical Research Center, Shaoxing People's Hospital, No.568, Zhongxing North Road, Shaoxing 312000, Zhejiang Province, China.
Wen-Hao WangDepartment of Medical Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang 261041, China.
Bao-Gang ZhangDepartment of Pathology, Shaoxing People's Hospital, No.568, Zhongxing North Road, Shaoxing 312000, Zhejiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast cancerferroptosisKeap1-Nrf2 signaling pathwaymiR-141-3ppaclitaxel resistance

Identifiers

PMID39308683
PMCPMC11414605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.